Freenome (NASDAQ:FRNM) Upgraded by BTIG Research to “Strong-Buy” Rating

BTIG Research upgraded shares of Freenome (NASDAQ:FRNM) to a strong-buy rating in a research note published on Monday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on the stock. Jefferies Financial Group started coverage on shares of Freenome in a research report on Monday. They issued a “buy” rating and a $17.00 price objective for the company. TD Cowen initiated coverage on shares of Freenome in a research report on Tuesday. They set a “buy” rating on the stock. Finally, Leerink Partners began coverage on shares of Freenome in a research note on Friday. They set an “outperform” rating and a $18.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Strong Buy” and a consensus target price of $17.33.

Freenome Trading Up 12.5%

FRNM stock opened at $13.00 on Monday. The stock has a market capitalization of $106.08 million, a P/E ratio of -216.63 and a beta of 0.35. Freenome has a 12 month low of $9.97 and a 12 month high of $14.26.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.